Unicycive Therapeutics, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing that the company issued a press release on that date announcing its financial results for the third quarter ended September 30, 2026, along with a business update.
Key Highlights
- Reporting period: Third quarter ended September 30, 2026.
- Filing date: November 16, 2026, the same date the press release was issued.
- Exchange listing: Common stock trades on the Nasdaq Capital Market under the symbol UNCY.
- Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
- Exhibit: The press release is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
- Signatory: The filing was signed by Shalabh Gupta, Chief Executive Officer.
Unicycive Therapeutics Files 8-K Covering Third Quarter 2026 Results
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) submitted a current report on Form 8-K to the Securities and Exchange Commission on November 16, 2026, under Item 2.02, which covers results of operations and financial conditions. According to the filing, the company issued a press release on that same date announcing its financial results for the third quarter ended September 30, 2026, and provided a business update. The full text of that press release was furnished as Exhibit 99.1.
The filing notes that the information disclosed under Item 2.02, including Exhibit 99.1, "is being furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing." The registrant is incorporated in Delaware and is headquartered at 4300 El Camino Real, Suite 210, Los Altos, CA 94022, according to the filing.
The company checked the box indicating it qualifies as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The registrant did not indicate that it has elected not to use the extended transition period for complying with new or revised financial accounting standards. The Form 8-K was signed by Shalabh Gupta, Chief Executive Officer, on November 16, 2026.
What Was Disclosed
Unicycive Therapeutics filed an 8-K on November 16, 2026, reporting that it issued a press release on the same date covering third-quarter 2026 financial results and a business update. The press release was furnished as Exhibit 99.1 and is not deemed "filed" under the Exchange Act.




Please wait processing your request...